Annual Financials for Cyclerion Therapeutics Inc.
Fiscal year is January-December. All values USD millions. |
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
Sales/Revenue
|
- | - | 4.51M | 2.3M | 3.94M | |
Sales Growth |
- | - | - | -49.06% | 71.69% | |
Cost of Goods Sold (COGS) incl. D&A |
1.75M | 1.53M | - | - | 472,000 | |
COGS excluding D&A |
- | - | - | - | - | |
Depreciation & Amortization Expense |
1.75M | 1.53M | 2.7M | 2.3M | 472,000 | |
Depreciation |
1.75M | 1.53M | 2.7M | 2.3M | 472,000 | |
Amortization of Intangibles |
- | - | - | - | - | |
COGS Growth |
- | -12.44% | - | - | - | |
Gross Income |
(1.75M) | (1.53M) | - | - | 3.47M | |
Gross Income Growth |
- | 12.44% | - | - | - | |
Gross Profit Margin |
- | - | - | - | 88.03% | NA |
|
2017 | 2018 | 2019 | 2020 | 2021 |
5-year trend |
SG&A Expense |
92.18M | 113.72M | 121.91M | 77.03M | 49.18M | |
Research & Development |
78.8M | 87.72M | 95.14M | 56.41M | 37.64M | |
Other SG&A |
13.37M | 26.01M | 26.77M | 20.62M | - | |
SGA Growth |
- | 23.38% | 7.19% | -36.81% | -36.15% | |
Other Operating Expense |
- | - | - | - | - | |
Unusual Expense |
- | - | 4.19M | 1.2M | (405,000) | |
EBIT after Unusual Expense |
- | - | (124.29M) | (78.23M) | (45.31M) | |
Non Operating Income/Expense |
- | - | (751,000) | 429,000 | (6.34M) | |
Non-Operating Interest Income |
- | - | 2.03M | - | - | |
Equity in Affiliates (Pretax) |
- | - | - | - | - | |
Interest Expense |
- | - | - | - | - | |
Interest Expense Growth |
- | - | - | - | - | |
Gross Interest Expense |
- | - | - | - | - | |
Interest Capitalized |
- | - | - | - | - | |
Pretax Income |
(93.92M) | (115.25M) | (123.01M) | (77.8M) | (51.65M) | |
Pretax Income Growth |
- | -22.71% | -6.73% | 36.75% | 33.62% | |
Pretax Margin |
- | - | - | - | -1,310.17% | NA |
Income Tax |
- | - | - | - | - | |
Income Tax - Current Domestic |
- | - | - | - | - | |
Income Tax - Current Foreign |
- | - | - | - | - | |
Income Tax - Deferred Domestic |
- | - | - | - | - | |
Income Tax - Deferred Foreign |
- | - | - | - | - | |
Income Tax Credits |
- | - | - | - | - | |
Equity in Affiliates |
- | - | - | - | - | |
Other After Tax Income (Expense) |
- | - | - | - | - | |
Consolidated Net Income |
(93.92M) | (115.25M) | (123.01M) | (77.8M) | (51.65M) | |
Minority Interest Expense |
- | - | - | - | - | |
Net Income |
(93.92M) | (115.25M) | (123.01M) | (77.8M) | (51.65M) | |
Net Income Growth |
- | -22.71% | -6.73% | 36.75% | 33.62% | |
Net Margin Growth |
- | - | - | - | -1,310.17% | NA |
Extraordinaries & Discontinued Operations |
- | - | - | - | - | |
Extra Items & Gain/Loss Sale Of Assets |
- | - | - | - | - | |
Cumulative Effect - Accounting Chg |
- | - | - | - | - | |
Discontinued Operations |
- | - | - | - | - | |
Net Income After Extraordinaries |
(93.92M) | (115.25M) | (123.01M) | (77.8M) | (51.65M) | |
Preferred Dividends |
- | - | - | - | - | |
Net Income Available to Common |
(93.92M) | (115.25M) | (123.01M) | (77.8M) | (51.65M) | |
EPS (Basic) |
(3.43) | (4.21) | (4.49) | (2.56) | (1.32) | |
EPS (Basic) Growth |
- | -22.71% | -6.81% | 43.04% | 48.44% | |
Basic Shares Outstanding |
27.4M | 27.4M | 27.38M | 30.4M | 39.14M | |
EPS (Diluted) |
(3.43) | (4.21) | (4.49) | (2.56) | (1.32) | |
EPS (Diluted) Growth |
- | -22.71% | -6.81% | 43.04% | 48.44% | |
Diluted Shares Outstanding |
27.4M | 27.4M | 27.38M | 30.4M | 39.14M | |
EBITDA |
(92.18M) | (113.72M) | (117.4M) | (74.74M) | (45.24M) | |
EBITDA Growth |
- | -23.38% | -3.23% | 36.34% | 39.47% | |
EBITDA Margin |
- | - | - | - | -1,147.69% | NA |